Adding to the flur­ry of IPOs be­fore May wraps up, two more biotechs filed in­ten­tions Thurs­day to go pub­lic: San Fran­cis­co’s Kezar Life Sci­ences hopes to raise $80.5 mil­lion, while Chica­go’s Xeris Phar­ma­ceu­ti­cals is shoot­ing for $75 mil­lion.

Both com­pa­nies plan to list on the Nas­daq, join­ing about a dozen oth­er biotechs that have trot­ted out to the pub­lic mar­kets this month. Just yes­ter­day, we saw Ma­gen­ta Ther­a­peu­tics, Kiniksa, Schol­ar Rock, and Aptinyx all file or wrap IPOs.

Kezar, which will list un­der the tick­er $KZR, has plans to use the IPO mon­ey to push for­ward its pipeline of au­toim­mune drugs. Spun out of Am­gen with small mol­e­cules from the plate of the for­mer Onyx Phar­ma­ceu­ti­cals, Kezar’s lead prod­uct is KZR-616. The drug is a se­lec­tive im­muno­pro­tea­some in­hibitor that’s about to be test­ed in a Phase Ib/II tri­al in lu­pus and lu­pus nephri­tis.

The IPO might al­so fu­el KZR-616 for the treat­ment of id­io­path­ic in­flam­ma­to­ry my­opathies and up to three ad­di­tion­al au­toim­mune in­di­ca­tions in­to Phase Ib or Phase II clin­i­cal tri­als, ac­cord­ing to the com­pa­ny’s S-1.

For Xeris, the IPO move comes a cou­ple months af­ter clos­ing a $55 mil­lion crossover round. The com­pa­ny plans to use the mon­ey for the com­mer­cial roll out of its lead prod­uct, a glucagon pen for di­a­bet­ics. Pro­ceeds will al­so go to­ward Xeris’ pipeline, which us­es the com­pa­ny’s glucagon for con­di­tions that re­quire ad­min­is­tra­tion over a longer pe­ri­od of time, in­clud­ing post-bariatric hy­po­glycemia and con­gen­i­tal hy­per­in­sulin­ism, among oth­er in­di­ca­tions.

Xeris plans to list un­der the tick­er $XERS.

DC District Court Judge Christopher Cooper today granted Vanda Pharma’s request to require the FDA to disclose more info on the complete response letter for its sleep disorder drug Hetlioz.

The melatonin receptor agonist is approved by the FDA to treat non-24-hour sleep-wake disorder, a circadian rhythm disorder. But in 2018 Vanda filed a supplemental application to market Hetlioz as a treatment for jet lag, which the FDA rejected in August 2019, with few details on what Vanda needed to correct course, according to the company.